Please login to the form below

Not currently logged in
Email:
Password:

drug pricing

This page shows the latest drug pricing news and features for those working in and with pharma, biotech and healthcare.

Countries hail ‘landmark’ drug pricing transparency resolution, despite watering down

Countries hail ‘landmark’ drug pricing transparency resolution, despite watering down

Member nations of the World Health Organisation have agreed a new resolution to demand greater transparency from the pharma industry in its drug pricing, which many have called a landmark decision. ... The resolution originally called for the WHO to

Latest news

  • Roche and NHS England hail pricing deal on MS drug Ocrevus Roche and NHS England hail pricing deal on MS drug Ocrevus

    Another pricing deal on high cost medicine. NHS England is claiming another successful negotiation with pharma after it agreed a lower price with Roche for its multiple sclerosis treatment Ocrevus. ... Roche says its trial data shows the drug is the

  • Orphan drugs market to soar to $224bn by 2024 Orphan drugs market to soar to $224bn by 2024

    The report warns the promise of innovative products such as Zolgensma and Lentiglobin “will only become reality if the innovation of drug companies is matched by innovation in the drug pricing ... Luxturna’s current list price is $425, 000 per eye,

  • Gottlieb signs off with flair – and pledge of further drug price commentary Gottlieb signs off with flair – and pledge of further drug price commentary

    This was based on Gottlieb’s bold approach to addressing unnecessary barriers to innovative medicines approvals, while at the same time tackling bottlenecks in generic drug approvals and pricing and competition ... This would once have been a radical

  • Trump budget targets rebates, out-of-pocket costs Trump budget targets rebates, out-of-pocket costs

    Away from drug pricing, the budget includes an increase in funding for HIV programmes, a 12.6% drop in funding for the National Institutes of Health (NIH) which is likely to ... The budget would fundamentally upset the successful Medicare drug benefit

  • Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

    But that war has been waged since 2016, when England’s cost-effectiveness watchdog first rejected the £100, 000 drug citing that the price was “ unsupportable”.. ... That deal included the approval of Vertex’s next-generation CF treatment Symkevi

More from news
Approximately 55 fully matching, plus 185 partially matching documents found.

Latest Intelligence

  • The Orkambi row explained The Orkambi row explained

    But the Orkambi row does stand out. One key factor is that back in 2013, Vertex managed to get a very favourable pricing deal for its first CF drug, Kalydeco. ... Canada also recently refused reimbursement and Spain is caught in a similar stand- off to

  • Deal Watch October 2018

    The Health Secretary, Alex Azar, has promised more to come on “fixing” drug pricing and introducing transparency into drug prices, and in the present political climate that can only be good ... Endocyte’s lead clinical product is 177Lu‐PSMA‐617,

  • Trust me, I’m from pharma Trust me, I’m from pharma

    However, controversies around drug pricing – fuelled by the unhelpful interventions of Martin Shkreli as the pin-up boy for big, bad pharma – have undermined progress and reinforced the view that the ... Individual companies are doing their bit too.

  • Patient outcomes in practice: delivering value that transforms lives Patient outcomes in practice: delivering value that transforms lives

    Providers, payers and manufacturers all have a role in achieving value, with increasing ethical pressure on drug pricing and resultant innovative, outcomes-based pricing models.

  • Drug pricing

More from intelligence
Approximately 7 fully matching, plus 31 partially matching documents found.

Latest appointments

  • Pfizer’s Emms takes up ABPI presidency Pfizer’s Emms takes up ABPI presidency

    Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the

  • Bayer's Martin Hesse moves to Daiichi Sankyo Europe

    Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era

    drug pricing?”. ... current barriers to progress in this area include perverse financial incentives, separation of hospital and drug budgets and inefficiencies within the system.

  • OPEN Health

    drug pricing?”.

  • Pricing's Point Man

    In the wake of the publication of the second edition of 'The Price of Global Health', Ed Schoonveld talks to William Looney. Pharm Exec Editor-in-Chief William Looney talks to Ed Schoonveld about the key policy and management issues around market

  • Turkey: Identifying the Growth Drivers

    This sector is dominated by pro-innovative drug prescribing physicians as well as a patient population who is willing to pay for a higher “quality” healthcare. ... Overall, while the public sector is characterised today byaggressive drug pricing

  • Article: The Colombia Conundrum

    drug pricing, as well as a streamlining of the essential drug list to remove some of the higher cost drugs. In a move to combat corruption, the EPS are set to ... This is exemplified by Sanofi’s 2012 acquisition of Genfar, which has resulted in the

More from PMHub
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics